EPS for Sonoma Pharmaceuticals, Inc. (SNOA) Expected At $-0.65

May 17, 2018 - By Peter Erickson

Analysts expect Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) to report $-0.65 EPS on June, 4.They anticipate $0.04 EPS change or 5.80 % from last quarter’s $-0.69 EPS. After having $-0.73 EPS previously, Sonoma Pharmaceuticals, Inc.’s analysts see -10.96 % EPS growth. The stock decreased 1.05% or $0.04 during the last trading session, reaching $3.78. About 11,989 shares traded. Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) has declined 45.71% since May 17, 2017 and is downtrending. It has underperformed by 57.26% the S&P500.

Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in the United States, Latin America, Europe, and internationally. The company has market cap of $17.93 million. The firm offers Microcyn line of products that are based on electrically charged oxychlorine small molecules designed to target a range of pathogens, such as viruses, fungi, and spores, as well as bacteria, including antibiotic-resistant strains. It currently has negative earnings. The Company’s products also include Celacyn, a prescription hypochlorous acid based scar management gel; Ceramax Skin Barrier Cream to manage dry itchy skin, minor skin irritations, rashes, and inflammation; Mondoxyne, a prescription oral tetracycline antibiotic for the treatment of various bacterial infections; Alevicyn, a prescription hypochlorous acid based atopic dermatitis product line to reduce itch and pain associated with various dermatoses; and SebuDerm, a prescription topical gel for the management of burning, itching, and scaling in seborrhea and seborrheic dermatitis.

More recent Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) news were published by: Globenewswire.com which released: “Sonoma Pharmaceuticals Receives Four New UAE Regulatory Approvals that Include Acne and Anti-Fungal Products” on April 17, 2018. Also Streetinsider.com published the news titled: “Sonoma Pharmaceuticals (SNOA) Appoints Marc Umscheid COO” on May 08, 2018. Globenewswire.com‘s news article titled: “Sonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer” with publication date: May 08, 2018 was also an interesting one.

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.